Ballicules.com

Aclidinium

TUDORZA PRESSAIR

What it isLong-acting muscarinic antagonist; COPD maintenance.

Why this oneRapid plasma hydrolysis distinguishes it from other LAMAs and limits systemic anticholinergic exposure.

What limits itIt is twice-daily maintenance, not rescue; urinary retention and narrow-angle glaucoma remain the key anticholinergic hazards.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
COPD — maintenance treatment of bronchospasmAdults1 oral inhalation 400 mcg BID400 mcg BID (~12 h apart)1 inhalation BID

Renal No adjustment needed

Hepatic Undefined

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy No adequate human data; no adverse developmental effects in animals at 15–20x the human inhaled dose (effects only at very high oral multiples).

Lactation No human data; present in rat milk — likely present in human milk.

NO BOXED WARNINGS

Principal riskAnticholinergic effects; twice-daily dosing

Cost, est. cash$200–$900/month

Generic entry2029 est.

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism4 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilityTremor, tachycardia or anticholinergic effects; excessive beta-agonist exposure can cause hypokalemia and arrhythmia.

Mechanism of action: Aclidinium ballicule

Aclidinium ballicule: receptor binding, kinetics and half-life diagram

Open Aclidinium in the interactive console ↗

Memory aids: mascots and interaction avatars

Aclidinium TUDORZA PRESSAIR mascot mnemonic cartoon
“A Clid in Two doors”

Open Aclidinium in the interactive console ↗